Method for selecting bronchial spasmolytic for treating acute period of bronchial asthma in child

FIELD: oil and gas industry.

SUBSTANCE: treating bronchial asthma (BA) in a child suffering from a mild, moderate or severe episode involves measuring a peak expiratory flow rate (PEFR). The child's age, height and sex are stated. The derived data are used to determine the adequate peak expiratory flow rate. That is followed by calculating the peak expiratory flow rate coefficient by specific formula. The following data of the past medical history are taken into account: the child's duration of the disease, the length of basic therapy, completed months, for one year preceding the acute period of the disease, as well as the presence of allergic diseases in immediate maternal and paternal relatives. A severity of the BA episodes is assessed. Each value derived from the past medical history is assigned with numerical values reflecting their prognostic significance. Heart rates are measured. Cardiointervalography is performed, and a vagosympathetic balance coefficient is determined. That is followed by calculating a risk of cardiohaemodynamic disorders (CHD) taking into account the above criteria by specific formula. If CHD<0.34, Fenoterol selective β2-adrenoceptor agonist is selected as a bronchial spasmolytic in the acute period of the disease. If 0.34≤CHD≤0.46, ipratropium bromide m-cholinoblocker is selected as the bronchial spasmolytic. If CHD>0.46, combined ipratropium bromide + Fenoterol is used as the bronchial spasmolytic.

EFFECT: reduced number of cardiovascular complications in the above category of children.

3 part-s

 

The invention relates to medicine, namely to Pediatrics, and can be used to select one of the three bronchodilatory drugs recommended for treatment of bronchial asthma in children in the period of exacerbation of the disease with mild, moderate or severe attack.

Bronchial asthma (BA) - current issue of Pediatrics and of clinical medicine in General. According to the Russian respiratory society, the prevalence of BA among children in our country is from 5.6 to 12.1% (Nenasheva NM Bronchial asthma: Pocket guide for clinicians. - M.: Publishing holding "Atmosphere", 2011. - P.9). BA in children leads to reduced quality of life, can cause disability, and sometimes dramatic outcomes (national programme of Bronchial asthma in children. The strategy of treatment and prevention". - 4th ed., Rev. and supplementary): dummy, 2012. - Page 16, 19).

BA is a chronic inflammatory disease of the Airways, which is attended by many cells and cellular elements. Chronic inflammation leads to the development of bronchial hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, feeling of stuffiness in the chest and coughing, particularly at night or early in the morning. These episodes are usually associated with widespread, but variable on its own is imagenote, obstruction of the respiratory tract, which is reversible under the effect of the treatment (global strategy for treatment and prevention of bronchial asthma (GINA). TRANS. from English. edited Achocalla. Revision 2011. - M.: the Atmosphere, 2011. - P.17).

The goal of treatment BA in the period of exacerbation of the disease is to eliminate obstruction of the bronchial tree by inhalation drugs: β2-agonists, anticholinergic agents and combined with bronchodilators (national programme of Bronchial asthma in children. The strategy of treatment and prevention". - 4th ed., Rev. and supplementary): dummy, 2012. - S. 113-115). All these drugs have a strong bronchodilatory effect; however, their impact on each child may be different from the point of view of their influence on cardiohemodynamic and can cause the development of a number of undesirable effects on the cardiovascular system, such as tachycardia, stenokardicheskie pain, decrease in diastolic, systolic pressure, heart arrhythmia, etc. So the problem of choosing broncholytic that have minimal negative impact on cardiohemodynamic is especially relevant in today's Pediatrics.

Conducted a search of the medical-scientific and patent literature found various ways of treatment choice BA in which erode of exacerbation.

So, according to the National programme of Bronchial asthma in children. The strategy of treatment and prevention" (4th ed., Rev. and ext. - M: mock-up, 2012) inhaled β2agonists are prescribed depending on the severity of the exacerbation: in case of mild attacks of BA, it is recommended to use short-acting β2agonists, moderate and severe exacerbation of BA best method of treatment and a rapid elimination of bronchoconstriction is the reassignment β2-agonists short-acting, and a synergistic effect is achieved by adding to β2-agonists, ipratropium bromide, or use of drugs with a fixed combination of ipratropium bromide+β2agonist.

The disadvantage of this method is the existence of negative effects of bronchodilator drugs on kardiogemodinamicheskuyu indicators in children with bronchial asthma, due to the absence of clear indications of individualized prescription-broncholytics the individual patient, taking into account the peculiarities of the child's body.

The closest technical solution adopted for the prototype, is the method of selection of drug-broncholytic for the treatment of ad in children in the period of exacerbation of the disease described in the patent of Russian Federation №2236219 (publ. 20.09.2004,) "Method of treatment of bronchial asthma in children in the period of exacerbation Zab the diseases". The method consists in the fact that they perform an examination of the child patient BA and measure the magnitude of the peak exhalation rate. Next, register the forced expiratory volume in 1 second, then carry out the inhalation of one of the drugs group β2agonist and re-assess the same performance. In case of increase relative to the original by more than 15% of a child is prescribed a treatment with this drug.

The disadvantage of this method is an increased risk of developing cardiovascular complications, since β2agonists often have a negative impact on the cardiovascular system of the individual child, as well as limited functionality of the method because it considers the criteria for the choice of only one of the three recommended drugs-broncholytics in the period of exacerbation of BA.

The objective of the invention is to develop a method of selecting one of three drugs-broncholytics, to minimize the negative impact on the cardiovascular system in children with bronchial asthma in the period of exacerbation.

The technical result is to reduce the number of complications from cardiovascular system in children with BA in the period of exacerbation of the disease, as well as expanding the functionality of the method.

Technicalscientific is achieved by in the period of exacerbation perform an examination of the child, the patient BA, and measure the magnitude of the peak exhalation rate (PSV), l/min. Determine the age of the child, (B)full years, its growth, cm, and gender, as well as proper peak exhalation rate (PSWD), l/min Calculate the ratio of peak exhalation rate (CPSV), %, according to the formula:

KPWith aIn=PWith aInPWith aInd×100%.

Then determine the factor gender (P), and for males the value of P is equal to 1 for females - 0. On the basis of anamnesis determine the duration of illness of the child (DZ)full years, and the duration of the basic therapy (PBT), of full months in the year preceding the exacerbation of the disease. Assess the severity of the attack (TA), the value of which in the case of a mild attack assigns a numeric value of 1 in the case of a moderate degree 2, in the case of severe - 3. Then explore the risk factors of close relatives on the maternal and paternal lines and determine the coefficient of heritability (H). In the case of allergic disease in close relatives by protec is Oh and paternal lines of size N assigns a numeric value, equal to 1, if not 0. Carry out the measurement of heart rate (HR, beats per minute. Perform cardiointervalography child and determine the value of the coefficient vagosympathetic balance (LF/HF). Next, calculate the value of risk kardiogemodinamicheskuyu violations (LTU) by the formula:

PKN=(-0,452)+0,031×-0,013×P-0,009×DZ+0,014×PBT+0,054×N IS 0.001×KSV+0,007×HR+0,003×TP-0,014×LF/HF.

If the condition PKN<0,34 as drug-broncholytic for treatment of the bronchial asthma in children in the period of exacerbation choose selective β2-adrenomimetic: fenoterol.

If the condition 0,34≤PKN≤0,46 as drug-broncholytic for treatment of the bronchial asthma in children in the period of exacerbation choose m-cholinergic antagonist: ipratropium bromide.

If the condition PKN>0,46 as drug-broncholytic for treatment of the bronchial asthma in children in the period of exacerbation choose combined bronchodilatory: ipratropium bromide+fenoterol.

Fenoterol, proprietary name "Berotec", registration number P # 015273/01 from 14.08.2008,, pharmacological group: β2-adrenomimetic selective. Fenoterol causes the relaxation of smooth muscles of the bronchi and blood vessels, as well as protects it from such bronchoconstricting factors, such as histamine, metacholine, cold air, allergens. After when the mA of the drug inhibited the release of mast cell mediators of inflammation. In addition, after receiving fenoterola in high doses, has increased mucociliary transport. Fenoterol also shows the properties of the breathing pacemaker.

Ipratropium bromide, proprietary name "Atrovent", registration number P # 015913/01 from 15.02.2010, pharmacological class m-cholinergic antagonist. Ipratropium bromide blocks m-cholinergic receptors of smooth muscle of the tracheobronchial tree, mainly at the level of large and medium bronchi, and inhibits reflex bronchoconstriction. Effectively prevents the narrowing of the bronchi, resulting from the inhalation of cigarette smoke, cold air, various bronchospasmolytic substances, and also inhibits the spasm of bronchi associated with influence of the vagi.

Ipratropium bromide+fenoterol, proprietary name "Berodual", registration number P # 015914/01 from 15.03.2010, pharmacological group - bronchodilatory combined β2-adrenomimetic selective+m-cholinergic antagonist). In a joint application as part of a combined drug of the two active substances bronchodilatory effect is achieved by acting on different pharmacological targets. These materials complement each other, resulting in enhanced spasmolytic effect on the bronchial muscles and provides more latitude terap whitesage steps in bronchopulmonary diseases, accompanied by constructia respiratory tract. The complementary effect is that to achieve the desired effect required a lower dose of β-adrenergic component that allows an individual to choose an effective dose with little or no side effects.

Detailed description of the method

In the period of exacerbation perform the examination of a child suffering from BA.

Measure the value of peak exhalation rate (PSV), l/min For this method peak flow reading (national programme of Bronchial asthma in children. The strategy of treatment and prevention". M., 2012. - S. 68) using, for example, MicroPeak peak flow meter, made by MICRO MEDICAL LTD (England), determine the values of peak exhalation rate (PSV), l/min

According to a survey of parents at the time of the study determine the age of the child, (B)full years.

Using a stadiometer, for example, medical metal stadiometer type MSC-233, measure the growth of the child, see

Determine gender of baby: boy or girl.

On the basis of the obtained data: age, height and gender of the child, determine the proper value of the peak exhalation rate the child (PSVd), l/min (table 5.2). "Good value PSV (l/min) (national program of Bronchial asthma in children. The strategy of treatment and prevention". M., 2012.- S. 68-69).

Then calculate coefficient peak exhalation rate (CPSV), %according to the formula:

KPWith aIn=PWith aInPWith aInd×100%.

Next, determine the factor of gender (P), and for males the value of P is equal to 1 for females - 0.

Based on history, according to the survey of one of the parents determine the duration of illness of the child (DZ)full years, and the duration of the basic therapy (PBT), of full months in the year preceding the exacerbation of the disease.

Assess the severity of the attack (TA), the value of which in the case of a mild attack assigns a numeric value of 1 in the case of a moderate degree of attack assigns a numeric value of 2, in case of severe attack assigns a numeric value equal to 3 (of the national program "Bronchial asthma in children. The strategy of treatment and prevention". - 4th ed., Rev. and supplementary): dummy, 2012. - S. 84-85).

Explore the risk factors of close relatives on the maternal and paternal lines: relatives in the direct ascending and descending lines: grandparents, full and half, having a common father or mother, brothers and sisters (Family code of the Russian Federation FZ dated 29.12.1995 No. 223, as amended on 13.02.2013, p. 2 item 14), and determine the coefficient of heritability (H). In the case of allergic disease in close relatives on the maternal or paternal lines of size N assign a numeric value of 1 in the absence of allergic disease in close relatives on the maternal or paternal lines of size N assign a numeric value of 0.

Measure heart rate (HR, beats per minute, using a stopwatch, for example TORRES SW-001.

Child perform cardiointervalography using, for example, cardioballistic "ANKAR-131", manufactured by Medicom MTD Ltd", , Taganrog (Russia). Next, the method of spectral analysis kardiointervalogrammy determine the value of the coefficient vagosympathetic balance (LF/HF) (ABC analysis of heart rate variability / Ivenz, Americana, Uaeac. - Stavropol. - 2002. - S. 31-34).

Calculate the value of risk kardiogemodinamicheskuyu violations (LTU) by the formula:

PKN=(-0,452)+0,031×-0,013×P-0,009×DZ+0,014×PBT+0,054×N IS 0.001×KSV+0,007×HR+0,003×TP-0,014×LF/HF.

If the condition PKN<0,34 as drug-broncholytic for treatment of the bronchial asthma in children in the period of exacerbation choose selective β2-adrenomimetic: fenoterol.

If the condition 0,34≤PKN≤0,46 as drugs the a-broncholytic for treatment of the bronchial asthma in children in the period of exacerbation choose m-cholinergic antagonist: ipratropium bromide.

If the condition PKN>0,46 as drug-broncholytic for treatment of the bronchial asthma in children in the period of exacerbation choose combined bronchodilatory: ipratropium bromide+fenoterol.

Practical feasibility of the proposed method is illustrated by examples from clinical practice.

Example 1: patient A., age 12, case history No. 1857/131, was admitted for examination and treatment at the children's city hospital №2, Rostov-on-don. Preliminary diagnosis: bronchial asthma, atopic asthma, moderate for the period of exacerbation. First obstructive syndrome developed at the age of 4 years on the background of acute respiratory diseases. An objective examination of the child: a serious condition. Pronounced expiratory dyspnea, respiratory rate 40 breaths a minute part of the auxiliary muscles pronounced, marked wheezing, frightened child, adopts a forced position of the body, it is difficult. Above the light percutere is determined by the sound box, the auscultatory - against the backdrop of weakened breathing scattered dry wheezing on exhalation from both sides. Heart sounds loud, the rhythm Ochsen.

For selection of drug-broncholytic for the treatment of ad in child A. in the period of exacerbation of the disease, a study was conducted coz the ACLs claimed method.

Measured value peak exhalation rate (PSV), l/min, using, MicroPeak peak flow meter, made by MICRO MEDICAL LTD (England) (national program of Bronchial asthma in children. The strategy of treatment and prevention". M., 2012. - S. 68). PSV=205 l/min

According to the survey of parents identified at the time of the study the age of the child, (B)full years. In=10 years.

Medical metal stadiometer type MSC-233, measured the growth of the child, which was 165 see

Determined the sex of the baby - boy: male.

On the basis of data obtained: age, growth and sex of the child determined the proper peak exhalation rate (PSWD), l/min (table 5.2. "Good value PSV (l/min) (national program of Bronchial asthma in children. The strategy of treatment and prevention M., 2012.- S. 68-69). PSVD=368 l/min

Then calculated the ratio of peak exhalation rate (CPSV), %:

KPWith aIn=PWith aInPWith aInd×100%=205368×100%=56%.

Further identified the factor gender (P). Because the patient A., boy, i.e. a male person, the value of N was taken equal the output 1.

Based on history, according to the survey of one of the parents determined the duration of illness of the child (DZ)full years. DZ=8 years. Because in the year preceding the exacerbation of the disease, basic therapy the child is not received, the duration of basic therapy was 0 months. PBT=0.

Assessed the severity of the attack (TA) (national program of Bronchial asthma in children. The strategy of treatment and prevention". - 4th ed., Rev. and supplementary): dummy, 2012. - S. 84-85). As was defined severe attack, the value of TA was assigned a value of 3. TP=3.

Investigated the risk factors of close relatives on the maternal and paternal lines. Because my grandmother on the paternal side was registered bronchial asthma, the magnitude of the coefficient of heredity was assigned a value of 1. H=1.

Measured heart rate (HR, beats per minute, using a stopwatch TORRES SW-001. HR=106.

The child complied with the cardiointervalography using cardioballistic "ANKAR-131", manufactured by Medicom MTD Ltd", , Taganrog (Russia). Method of spectral analysis of kardiointervalogrammy determined the value of the coefficient vagosympathetic balance (LF/HF). LF/HF=4,3.

Calculated the value of risk kardiogemodinamicheskuyu violations (LTU) by the formula:

PKN=-0,452)+0,031×-0,013×P-0,009×DZ+0,014×PBT+0,054×N IS 0.001×KSV+0,007×HR+0,003×TP-0,014×LF/HF=(-0,452)+0,031×12-0,013×1-0,009×8+0,014×1+0,054×1-0,001×56+0,007×106+0,003×3-0,014×4,3=(-0,452)+0,372-0,013-0,072+0+0,054-0,056+0,742+0,009-0,06=0,524.

Since it was made a condition PKN=0,524>0,46, patient A. as drug-broncholytic in the period of exacerbation were assigned to the treatment combination drug ipratropium bromide+fenoterol.

After the treatment with this drug within 7 days by inhalation 3 times a day in combination with isolationism a glucocorticosteroid: pulmicort dose of 0.5 mg 2 times a day, and expectorant drug: Ambroxol at a dose of 5 ml 3 times a day, noted improvement in respiratory function in the form of increase of PSV values to normal values - 370 l/min

The results of echocardiographic and electrocardiographic studies revealed no violations of kardeogemodyinamiki. Child on day 9 was discharged from hospital in satisfactory condition.

A survey of the cardiovascular system in the long term also revealed no violations of kardeogemodyinamiki.

Example 2: sick girl And., 10 years, the case history No. 1549/246, was admitted for examination and treatment at the children's city hospital №2, Rostov-on-don. Preliminary diagnosis: bronchial asthma, atopic asthma, lung during. At admission had complaints of shortness of breath, cough, shortness of breath. First obstructive syndrome developed at the age of 3 years on the background of acute respi atomnogo disease. In the next 1 year child endured obstructive bronchitis, not accompanied by fever. On physical examination, the child's condition was regarded as moderate. Breathing shallow: 26 of respiratory movements per minute, with soft strong participation auxiliary muscles, wheezing observed at the end of exhalation, physical activity and conversation saved. Above the light percutere defined sound with boxed shade, auscultatory - against the hard breathing scattered dry wheezing on exhalation. The distinct heart sounds, rhythm Ochsen.

For selection of drug-broncholytic for the treatment of ad in child And. in the period of exacerbation of the disease, a study was conducted according to the claimed method.

Measured value peak exhalation rate (PSV), l/min, using, MicroPeak peak flow meter, made by MICRO MEDICAL LTD (England) (national program of Bronchial asthma in children. The strategy of treatment and prevention". M., 2012. - S. 68). PSV=135 l/min

According to the survey of parents identified at the time of the study the age of the child, (B)full years. In=10 years.

Medical metal stadiometer type MSC-233, measured the growth of the child, which was 125 see

Determined the sex of child: female.

On the basis of the received Yes is data: age, growth and sex of the child determined the proper peak exhalation rate (PSWD), l/min (table 5.2. "Good value PSV (l/min) (national program of Bronchial asthma in children. The strategy of treatment and prevention". M., 2012.- S. 68-69). PSVD=156 l/min

Then calculated the ratio of peak exhalation rate (CPSV), %:

KPWith aIn=PWith aInPWith aInd×100%=125156×100%=86%.

Further identified the factor gender (P). Because the patient And., girl, i.e. a female person, the value of P is assumed to be 0.

Based on history, according to the survey of one of the parents, determined the duration of illness of the child (DZ)full years. DZ=7 years. As a child in the last 3 months preceding the exacerbation of the disease, as a basic anti-inflammatory therapy received inhaled corticosteroids, the duration of basic therapy (PBT) amounted to 3 months. PBT=3.

Assessed the severity of the attack (TA) (national program of Bronchial asthma in children. The strategy of treatment and prevention". - 4th ed., Rev. and supplementary):the Original layout 2012. - S. 84-85). As was defined mild attack, the value of TA was assigned a value of 1. TP=1.

Investigated the risk factors of close relatives on the maternal and paternal lines. Because of allergic disease in close relatives on the maternal and paternal lines have been identified, the magnitude of the coefficient of heredity was assigned a value of 0. N=0.

Measured heart rate (HR, beats per minute, using a stopwatch TORRES SW-001. HR=96.

The child complied with the cardiointervalography using cardioballistic "ANKAR-131", manufactured by Medicom MTD Ltd", Taganrog (Russia). Method of spectral analysis of kardiointervalogrammy determined the value of the coefficient vagosympathetic balance (LF/HF). LF/HF=0,4.

Calculated the value of risk kardiogemodinamicheskuyu violations (LTU) by the formula:

PKN=(-0,452)+0,031×-0,013×P-0,009×DZ+0,014×PBT+0,054×N IS 0.001×KSV+0,007×HR+0,003×TP-0,014×LF/HF=(-0,452)+0,031×10-0,013×0-0,009×7+0,014×3+0,054×0-0,001×86+0,007×96+0,003×1-0,014×0,4=(-0,452)+0,31+0-0,063+0,042+0-0,086+0,672+0,003-0,0056=0,42.

Since it was made a condition 0,34≤PKN=0,42≤0,46, the patient And. as drug-broncholytic in the period of exacerbation were assigned to the treatment m-cholinergic antagonist ipratropium bromide. After the treatment with this drug within 7 days by inhalation 3 times a day in combination is isolationism a glucocorticosteroid: pulmicort dose of 0.5 mg 2 times a day, expectorant drug: Ambroxol at a dose of 5 ml 3 times a day, noted improvement in respiratory function in the form of increase of PSV values to normal values - 160 l/min

The results of echocardiographic and electrocardiographic studies revealed no violations of kardeogemodyinamiki. The child on the 8th day was discharged from hospital in satisfactory condition.

A survey of the cardiovascular system in the long term also revealed no violations of kardeogemodyinamiki.

Example 3: a patient Century girl, 9 years old, the case history No. 1536/345, was admitted for examination and treatment at the children's city hospital №2, Rostov-on-don. Preliminary diagnosis: bronchial asthma, atopic asthma, lung during. At admission had complaints of shortness of breath, cough, shortness of breath. First, the diagnosis of ad was placed at the age of 2 years. Annually celebrated asthma in autumn. On physical examination, the child's condition was regarded as moderate. Breathing shallow (24 respiratory movements per minute) with mild strong participation auxiliary muscles, wheezing observed at the end of exhalation, physical activity and conversation saved. Above the light percutere defined sound with boxed Otten is om, auscultatory - against the hard breathing scattered dry wheezing on exhalation. The distinct heart sounds, rhythm Ochsen.

For selection of drug-broncholytic for the treatment of ad in child And. in the period of exacerbation of the disease, a study was conducted according to the claimed method.

Measured value peak exhalation rate (PSV), l/min, using a MicroPeak peak flow meter, made by MICRO MEDICAL LTD (England) (national program of Bronchial asthma in children. The strategy of treatment and prevention". M., 2012. - S. 68). PSV=212 l/min

According to the survey of parents identified at the time of the study the age of the child, (B)full years. In=9 years.

Medical metal stadiometer type MSC-233 measured the growth of the child, which was 140 see

Determined the sex of child: female.

On the basis of data obtained: age, growth and sex of the child determined the proper peak exhalation rate (PSVd), l/min (table 5.2. "Good value PSV (l/min) (national program of Bronchial asthma in children. The strategy of treatment and prevention". M., 2012.- S. 68-69). PSVD=236 l/min

Then calculated the ratio of peak exhalation rate (CPSV), %:

KPWith aIn=PWith aInPWith aInd 100%=212236×100%=90%.

Further identified the factor gender (P). Because the patient And., girl, i.e. a female person, the value of P is assumed to be 0.

Based on history, according to the survey of one of the parents determined the duration of illness of the child (DZ)full years. DZ=7 years. As a child in the year preceding the exacerbation of the disease, basic treatment is not received, the duration of basic therapy (PBT) was 0 months: PBT=0.

Assessed the severity of the attack (TA) (national program of Bronchial asthma in children. The strategy of treatment and prevention". - 4th ed., Rev. and supplementary): dummy, 2012. - S. 84-85). As was defined mild attack, the value of TA was assigned a value of 1. TP=1.

Investigated the risk factors of close relatives on the maternal and paternal lines. Because of allergic disease in close relatives on the maternal and paternal lines have been identified, the magnitude of the coefficient of heredity was assigned a value of 0. N=0.

Measured heart rate (HR, beats per minute, using a stopwatch TORRES SW-001. HR=80.

The child has completed the device is Yu with the help of cardioballistic "ANKAR-131", manufactured by Medicom MTD Ltd", , Taganrog (Russia). Method of spectral analysis of kardiointervalogrammy determined the value of the coefficient vagosympathetic balance (LF/HF). LF/HF=3,5.

Calculated the value of risk kardiogemodinamicheskuyu violations (LTU) by the formula:

PKN=(-0,452)+0,031×-0,013×P-0,009×DZ+0,014×PBT+0,054×N IS 0.001×KSV+0,007×HR+0,003×TP-0,014×LF/HF=(-0,452)+0,031×9-0,013×0-0,009×7+0,014×0+0,054×0-0,001×90+0,007×80+0,003×1-0,014×3,5=(-0,452)+0,279+0-0,063+0+0-0,09+0,56+0,003-0,049=0,188.

Since it was made a condition PKN=0,188<0,34, the patient Century as drug-broncholytic in the period of exacerbation were assigned to the treatment β2-adrenomimetics fenoterol. After the treatment with this drug for 6 days by inhalation 3 times a day in combination with isolationism a glucocorticosteroid: pulmicort dose of 0.5 mg 2 times a day, and expectorant drug: Ambroxol at a dose of 5 ml 3 times a day, noted improvement in respiratory function in the form of increase of PSV values to normal values to 240 l/min

The results of echocardiographic and electrocardiographic studies revealed no violations of kardeogemodyinamiki. Child at day 7 was discharged from hospital in satisfactory condition.

A survey of the cardiovascular system in the long term also revealed no violations from the side of kardeogemodyinamiki.

Using the proposed method in children's city hospital №2, Rostov-on-don, was selected drug-broncholytic for the treatment of ad in each child of a group of 82 children in the period of exacerbation. Among the surveyed children easy attack was observed in 24 patients (to 29.27%), moderate -, 28 (34,15%), heavy attack BA - 30 patients (36,58%). The average age of the children was 11,93±3,38 years. The vast majority of patients received basic therapy (75,35%), the average duration of which was 2,97±0.45 and months. The average age of onset of disease - 5,47±0,40 years. The br52.11% of the surveyed children was noted burdened allergological anamnesis.

All children were treated according to conventional regimens, the choice of drug-broncholytic was carried out by the method presented in this application. In all the examined patients with BA in the period of exacerbation of the disease was not observed complications in the cardiovascular system, which confirmed the high efficacy of this method.

Retrospective analysis of 118 histories of children with asthma in the period of exacerbation of the disease, the treatment which was carried out using inhaled glucocorticosteroids, salt preparations using broncholytics in General is rinati method showed that in a group of 118 children had complications of the cardiovascular system: in 35% of patients there was a trend to increased blood pressure; in assessing the condition of a small circle of blood circulation in 42.5% of cases, there had been a statistically significant increase of blood flow velocity and pressure in the pulmonary artery, indicating the formation of pulmonary hypertension; 3.7% of patients had a reduction transtricuspid gradient less than 1, which is an early marker of diastolic dysfunction of the myocardium of the right ventricle.

Thus, compared with the conventional method proposed method of selection of drug-broncholytic prevents the development kardiogemodinamicheskuyu violations.

The method of selection of drug-broncholytic for the treatment of bronchial asthma (BA) the child in the period of exacerbation of the disease, including patient assessment and determination of the peak exhalation rate (PSV), l/min, characterized in that it further determine the age of the child, (B)full years, its growth, cm, gender, and tribute to the peak exhalation rate (PSWD), l/min, calculate the ratio of peak exhalation rate (CPSV), %, according to the formula:
KPWith aIn=PWith aInP With aInd×100%,
determine the factor of gender (P), and for males the value of P is equal to 1 for females - 0, determine the duration of disease (HD), full of years and the duration of the basic therapy (PBT), of full months in the year preceding the exacerbation of the disease, assess the severity of the attack (TA), the value of which in the case of a mild attack assigns the value of 1 if moderate degree 2, in the case of severe - 3; investigate risk factors in relatives on the maternal and paternal lines and determine the coefficient of heritability (H), the value of which in the case of allergic disease in close relatives on the maternal and paternal lines assign a numeric value equal to 1, if not 0; conduct measurement of heart rate (HR, beats per minute; perform cardiointervalography and determine the value of the coefficient vagosympathetic balance (LF/HF), then compute the value of the indicator of risk kardiogemodinamicheskuyu violations (LTU) by the formula:
PKN=(-0,452)+0,031×-0,013×P-0,009×DZ+0,014×PBT+0,054×N IS 0.001×KSV+0,007×HR+0,003×TP-0,014×LF/HF, and the condition of the PKN<0,34 as drug b is Analitica for treatment of the bronchial asthma in children in the period of exacerbation of zabolevaniya choose fenoterol, if the condition 0,34≤PKN≤0,46 choose ipratropium bromide, the condition of the PKN>0,46 - ipratropium bromide/fenoterol.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method enables a cycloergometric pre-measurement of exercise tolerance according to PWC170 test, a minute pulmonary ventilation (MPV) by means of pneumotachography, and arterial oxygenation by means of an ear sensor of an oxyhemograph. If observing a decrease of exercise tolerance at power less than 1 W/kg for 2 minutes, an increase of MPV more than 350% of initial values, with an increase of arterial saturation more than 98%, a treatment starts with a manual therapy covering spinal motion segments in the number of 3 procedures every two days. That is followed by a balneotherapy in the form of thermal low-radon siliceous baths at temperature 38°C, for 10 minutes in the number of 6 procedures within the therapeutic course.

EFFECT: method reduces probability of chronic processes in bronchi, reduces rate of recurrent bronchitis ensured by normalising the external respiration function by eliminating the functional blocks in the spinal motor segments.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pulmonology and allergology, and can be used for treating bronchial asthma (BA) in children and adolescents. That is ensured by determining clinical, functional, cytological, biochemical, immunological allergic inflammation activity markers (AIAMs). These markers are evaluated according to the developed scales. The total score is calculated according to each scale separately. Allergic inflammation activity indices (AIAIs) are calculated by the certain formulas taking into account the calculated total scores according to each scale. An integrative AIAI is calculated. An allergic inflammation activity degree (AIAD) is determined depending on the integrative AIAI. If the AIAD is 0, therapy required for the stage I basic anti-inflammatory therapy of BA is conducted. The 1st AIAD requires therapy corresponding to the stage II basic therapy. The 2nd AIAD requires therapy corresponding to the 3rd stage therapy; the 3rd AIAD provides therapy corresponding to the 4th stage basic anti-inflammatory therapy of BA.

EFFECT: method provides a differentiated approach to selecting a volume of basic therapy of the given disease by accurate diagnosing of a degree of activity of the allergic inflammatory process in the airway walls that in its turn provides reducing a rate of attacks and length of aggravations in prolonging BA remission.

2 ex, 10 tbl

FIELD: medicine.

SUBSTANCE: vital capacity, linear blood flow velocity in the inferior vena cava (IVC) in a subdiaphragmatic segment, a subdiaphragmatic diameter of the inferior vena cava, a peak expiratory flow rate and the Tiffeneau index are determined. The derived values are substituted in a mathematical formula, and the value S as a patient's severity score is determined. If S<100, the patient's severity is considered to be moderate with an osteosynthesis performed after a drainage of the pleural cavity. The values S>100 enable stating the patient's severe condition with a high probability of intrapleural complications. A repeated spirography and duplex examination of the IVC are performed in the given category of the patients after sanitation of the pleural cavity and removal of the drain tube. The values S<100 require performing an osteosynthesis; if S>100, the patient's follow-up and therapeutic actions are prescribed. The method enables evaluating the patient's severity if observing the combined injuries of a chest and extremity segments and selecting a correct therapeutic approach by the adequate use of conservative and surgical methods.

EFFECT: improving the clinical outcome in the patients suffering from the given pathology, avoiding various complications both of the chest organs, and of locomotor apparatus.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pulmonology, and can be used for predicting achievement of control over bronchial asthma (BA). For this purpose, spirogram of quiet breathing is registered for 3 minutes in patients with mild persisting or medium-severe persisting course in attack-free period before beginning therapy. After that, standard deviation of respiratory cycle duration (SD) is calculated. Then, instantaneous volumetric rate of forced exhalation at the level of 50% vital lung capacity (IVR50%) is determined. Two doses of short action β2-agonist are introduced in inhalation way. After 15 minutes IVR50% is re-registered. After that, degree of IVR50% change in response to medication introduction is calculated in %. Then discriminant equation D=0.923×IVR50%+68.766×SD, where D is discriminant function, with boundary value 77.0, is solved. If D value is equal or higher than boundary value, it is predicted that BA control will not be reached after 6 months of standard therapy. If D value is lower than boundary value, it is predicted that BA control will be reached.

EFFECT: method makes it possible to start adequate pharmacotherapy in patients with low probability of obtaining control over BA in due time and eliminate introduction of large doses of inhalation glucocorticosteroids to patients with predicted achievement of disease control.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to anesthesiology and intensive therapy and can be used in case of necessity to estimate degree of patient's metabolic and cardiorespiratory adaptation. For this purpose during operation and intensive therapy successive inhalation of gas mixture with 51% (FiO2=0.51) and 21% (FiO2= 0.21) content of oxygen is carried out. After that, consumption of oxygen and release of carbon dioxide at each stage are determined, and power of anaerobic threshold by FiO2 in gas mixture, corresponding to the moment of anaerobic threshold achievement, is calculated. If power of anaerobic threshold is >0.14, degree of patient's metabolic and cardiorespiratory adaptation is considered to be low. If index value is <0.1, degree of patient's metabolic and cardiorespiratory adaptation is considered to be high. If index value is 0.1-0.14, degree of patient's metabolic and cardiorespiratory adaptation is considered to be medium.

EFFECT: method makes it possible to ensure reduction of probability of development of hypoxic complications in critical patients due to determination of degree of metabolic and cardiorespiratory adaptation during operation and intensive therapy, including mode of monitoring.

1 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and medical equipment. Bipolar method of poly-frequency impedancemetry . Module value of impedance (Z) and phase angle (φ) at frequencies 20, 98, 1000, 5000, 10000, and 20000 Hz of alternating electric current of low power during inhalation of 0.9% of sodium chloride solution. In the process of measurement the first electrode is installed into mouthpiece of ultrasound nebuliser, the second is placed on chest skin or in the region of examination, or joining electrodes, installed on symmetrical sections of chest. If deviations of Z and/or φ values are less than 5 or more than 95 percentiles from the normal values, impairment of respiratory function is diagnosed. To carry out diagnostics computer appliance, which contains measurement unit, mouthpiece, nebuliser inhalator, as well as electrodes, one of which is installed on patient's chest, the other is installed in mouthpiece of ultrasound nebuliser inhalator.

EFFECT: invention makes it possible to increase reliability of respiratory function diagnostics.

2 cl, 2 dwg, 18 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pulmonology, and can be applied for predicting frequency of exacerbations of chronic obstructive lung disease (COLD) in men. For this purpose volume of forced inhalation for 1 second (VFI1) and value of general blood testosterone (T) are determined. After that coefficient of COLD exacerbations (Cexacerb.) is calculated by specific mathematical formula. If Cexacerb. value is less than 2.065, not more than two exacerbations per year are predicted. If Cexacerb. value equals or is higher than 2.065, three and more exacerbations per year are predicted.

EFFECT: method makes it possible to predict course of the disease in remote period of time and in correct performed therapy in case of necessity.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pulmonology, and can be used in treatment and examination of patients with bronchial asthma. For this purpose measurement of VFE1 is carried out. After that, test with isocapnic hyperventilation with cold air (IHCA) is performed. After that decrease of volume of forced exhalation (ΔVFE1) is studied. Final temperature of exhaled air (T°fin) is measured immediately after IHCA. Prediction is performed by means of discriminant equation D=2.73×ΔVFE1(%)+0.39×T°fin. (°C), where D is discriminant function with the boundary value 54.02. If D is less than the boundary value, development of polypous rhinosinusitis in patients with bronchial asthma is predicted. If D equals or is higher than the boundary value, absence of development of polypous rhinosinusitis in patients with bronchial asthma is predicted.

EFFECT: method makes it possible to provide the most optimal tactics of treating patients with bronchial asthma due to realisation of prediction by functional parameters at the initial stage.

3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pulmonology and can be used for predicting course of moderate to severe chronic obstructive lung disease (COLD). Volume of forced exhalation for the first second (VFE1) is measured. Bronchi-provoking pharmacological test with 0.33% methacholine solution is performed. Change of volume of forced exhalation for the first second (ΔVFE1) from the initial value is registered. On the basis of said parameters determined are: post-bronchodilation residual volume of lungs and degree of hypersensitivity of respiratory ways, which are considered to be a risk factor. Other risk factors: patient's age, disease duration, number of exacerbations pre year, are also taken into account. Each risk factor is given a numerical value and gradation, which are used to determine prognostic coefficients F1 and F2 with further comparison of these values. If F2 is larger than F1, unfavourable course of COLD with progressing dyspnea is predicted. If F1 value is larger than F2, favourable clinical course of disease with low risk of severe dyspnea development is predicted.

EFFECT: method makes it possible to predict clinical course of said disease and activate pathogenetically justified therapy in due time.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pulmonology, therapy and allergology and can be used for predicting risk of development of uncontrolled course of severe bronchial asthma (BA). For this purpose, parameters of respiratory function: PEF, FVCL, MVR25, MVR50, MVR75, FEV1 and FEV1 after the test with salbutamol are determined and ΔFEV1 is calculated. Value of ACT-test and indices of gas concentration in exhaled air CO, NO, NO2 are also taken into account. After that, indices of probability of referring patient to group with high (R1) and low risk (R2) of development of uncontrolled course of severe BA are calculated by certain mathematical formulas. If R1 > R2, high risk of development is predicted, if R1 < R2, low risk of development of uncontrolled course of said disease is predicted.

EFFECT: method makes it possible to predict probability of development of uncontrolled BA course in response to basic therapy and in this way provides possibility to elaborate optimal plan for management of each patient.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to methods and devices of identifying reasons of cardiac rhythm disturbance. Method consists in perception of signals of heart excitation in multitude of locations with application of multitude of sensors, collection of data from multitude of sensors. Collected data include sensor location for each sensor and time of heart excitation origination in each sensor location, so multitude of times of excitation origination in multitude of locations of sensors are collected, and then their sequence is formed. Obtained data are then analysed and approximate central areas, connected with excitation pathway, pointing to reasons of said cardiac rhythm disturbance, are determined.

EFFECT: application of invention makes it possible to determine location of reasons of cardiac rhythm disturbance for the following treatment with minimally invasive, surgical and other methods.

37 cl, 16 dwg

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine and can be applied as a method of predicting an unfavourable outcome of cerebral circulation impairment. A level of stab neutrophils and erythrocyte sedimentation rate are determined in blood tests. The presence of displacement of midline brain structures is identified on a computer tomography scan. A number of ventricular and supraventricular extrasystoles is determined on an electrocardiogram. If the value of stab neutrophils is 3.5-4.5%, erythrocyte sedimentation rate is 12-20 mm/h, displacement of midline structures is 7 mm and more, an average day value of ventricular and supraventricular extrasystoles is respectively 490-670 and 1530-1880, and in case of blood presence in liquor, an unfavourable outcome of cerebral circulation impairment is predicted.

EFFECT: method makes it possible to increase the prediction reliability.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, labour safety, vocational selection of rescue workers. The invention can be used for vocational selection in the sectors of industry using personal protective equipment, as well as for the workers labour safety in the sectors of industry with harmful working conditions. The method involves vocational selection and duty control on the basis of electroencephalogram (EEG) values and cardiological findings. The examination is performed prior to and when using the personal protective equipment. The cardiological examination involves assessing the heart rate variability with using the amplitude-frequency spectrum Fourier analysis VLF at a vibration frequency within the range of 0.0033-0.04 Hz, LF - at a frequency of 0.05-0.15 Hz and HF - at a frequency of 0.16-0.80 Hz, and is five-staged: initial resting state, mental work load, recovery of mental work load, hyperventilation load, recovery of hyperventilation load. At the beginning, the heart rate variations and EEG are examined prior to using the personal protective equipment. If any of the five stages of the heart rate variation examination shows the pulse more than 90 beats per minute, as well as changes from the normal values of: approximating entropy - less than 180, LF - less than 6 point, an alpha wave amplitude - to 12 vibrations per second and the presence of the paroxysmal activity by EEG, the prevailing sympathetic nervous system is stated, or if any stage of the heart rate variation examination shows the pulse less than 60 beats per minute, as well as changes from the normal values of: blood pressure - more than 140/90 mmHg, VLF - more than 130 points, HF - more than 16 points, an alpha wave amplitude - less than 25 mcV, the prevailing parasympathetic nervous system is stated; a low level of adaptation to the personal protective equipment is predicted, and a rescue work is not recommended during the vocational selection; the examination is terminated. If the heart rate variation and EEG prior to using the personal protective equipment fall within the normal values, the heart rate variation when using the personal protective equipment is started with the patient examined when using the personal protective equipment and performing a cycle ergometer test, and recording the hyperadaptotic changes of the assessed values: VLF - more than 130 points in relation to the normal value when using the personal protective equipment and LF and HF vibrations; an incomplete or unfinished adaptation to the personal protective equipment, and the rescue worker is suspended from work for several hours; if VLF is more than 130 points recorded 10-15 min after activating the personal protective equipment, a good adaptation level to the personal protective equipment is predicted.

EFFECT: method enables assessing the vegetative nervous function and predicting the rescue workers' adaptation level to the personal protective equipment.

11 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention can be used to identify a high risk of developing impaired glucose tolerance in patients with stable effort angina with underlying administering beta-adrenergic blocking agents with no additional vasodilating properties. Therapy is preceded by conducting 2 exercise tests on the same day to achieve a threshold load power according to the same protocol, initially and 2 hours after administering a single dose of the beta-adrenergic blocking agents. If observing an interval gain of 120 seconds and more from the beginning of the load to the angina attack and/or reduction of an ischemic ST segment on the electrocardiogram not less than 1 mm at the 2nd load as compared to the 1st load, a risk of impaired glucose tolerance is considered to be high. A glucose tolerance test is carried out in these patients 4-5 weeks after the scheduled administration of the beta-adrenergic blocking agents. If impaired glucose tolerance is detected, administering the beta-adrenergic blocking agents is withdrawn. If the 2nd load as compared to the 1st load shows an interval to the angina attack and/or reduction of the ischemic ST segment on the electrocardiogram at a depth not less than 1 mm increasing less than by 120 seconds, a risk of developing impaired glucose tolerance is considered to be negligible. Treatment of these patients with the beta-adrenergic blocking agents is continued without the glucose tolerance test required.

EFFECT: method provides preventing carbohydrate metabolic disorders by the early identification of the high risk of developing impaired glucose tolerance in the given patients by detecting a compensatory increase of the glucose consumption with insulin resistance and a lower availability of free fatty acids to provide myocardial energy needs.

6 ex

FIELD: medicine.

SUBSTANCE: according to one version, the method involves studying the heart rate variability and a motion state, dietary nutrition, baths with mineral water, mineral water intake, physiotherapeutic procedures. The dietary regimen is specified taking into account the measured immunoglobulin IgG values to detect food intolerance and elimination thereof from the nutrition. Low-salt sulphate calcium-magnesium-sodium mineral water is taken. The baths are taken with mineral water from a water-bearing formation of Middle Devonian at a depth of 1100-1278 m by using mineral water representing a salt brine of Devonian Sea M 240-260 g/dm3 of sodium-chloride composition Cl>95, Na++K+>80 mg-eq.%, with an acid reaction of the medium, at pH 4.7-5.5. According to the other version, the method additionally contains massage sessions and acupuncture taking into account the patient's heart rate variability.

EFFECT: group of inventions provides more effective health improvement by taking into account individual food intolerance and the patient's autonomic nervous system features.

2 cl, 3 ex

FIELD: medicine.

SUBSTANCE: continuous electric cardiac signal (ECS) is filtered and presented in the form of discrete readouts. Then it is smoothed by amplitude averaging of adjacent readouts of the electric cardiac signal. That is followed by isolating R-R interval and a cardiac cycle, limiting a search area of the beginning of the ventricular repolarisation to the left and right in relation to R wave, specifying two numbers of the ECS readouts X1={xa÷xb} and X2={xc÷xd}in the search area, calculating arithmetical mean amplitudes M1 and M2 of the readouts from the numbers X1 and X2, calculating an absolute difference of mean ECS amplitudes D=|M1-M2|, and unless D gets more than the ECS limit, calculating M1, M2 and D is repeated for the numbers X1 and X2 displaced one element to the right until reaching the right limit of the search area, isolating the readout Jj,i=xa in each j-th deflection for which D falls below the ECS limit. Thereafter the latest Jj,i value is determined; the determined value represents the beginning of ventricular repolarisation in the i-th cardiocycle.

EFFECT: method provides higher reliability of isolating R-wave and stating the beginning of ventricular repolarisation.

13 dwg

FIELD: medicine.

SUBSTANCE: auricular extrasystole recorded in the patient is analysed by calculating a relative coupling interval (RCI). The value is calculated by dividing a cardiac contraction interval immediately preceding the auricular extrasystole by the coupling interval. The derived RCI is assessed. If the value exceeds the value of 1.7, a high risk of developing paroxysmal atrial fibrillation is diagnosed in the patient.

EFFECT: method enables predicting a high probability of developing paroxysmal atrial fibrillation within the next hour.

2 ex, 2 dwg, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly cardiology. A 24-hour electrocardiogram is recorded in a post-myocardial infarction patient s. A standard mean deviation of RR intervals is evaluated and low and high frequency waves and QT interval variability are related. An echocardiography is recorded to evaluate an ejection fraction. The clinical findings are used to predict severity of arrhythmia syndrome.

EFFECT: method enables determining severity of arrhythmia syndrome more accurately without any load tests thereby reducing a health risk.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to methods of functional diagnostics in cardiology. Stress-echocardiographic examination with application of transesophageal electrical stimulation of atria is carried out. Electric stimulation is carried out with step-by-step change of HR value in continuous mode. Stimulation starts from rate which is 20 beats lower than submaximal HR, with further increase of rhythm frequency by 10 p./min at each following minute until submaximal HR is achieved. After that electric stimulation continues at maximal HR within time period up to 3 minutes, when echocardiographic criteria of stress-induced ischemia of myocardium appear, electric stimulation is stopped.

EFFECT: invention makes it possible to increase diagnostic significance of the method in a reliable way with reduction of examination time.

2 cl, 1 ex, 2 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely to devices for carrying out magnetic resonance tomography. Magnetic resonance system, which includes system of magnetic resonance visualisation, contains, contains main magnet, unit of gradient coils, high-frequency unit and monitor for analysis of signals from electrodes. Monitor includes printed circuit board with sites for soldering and connector, connecting electrode leads with printed circuit board and including electric connecting outlets, upper lugs and lower lugs. Connector also includes two snapping brackets, gearing with locks in printed circuit board, preventing separation of connector and printed circuit board and rotation of connector around vertical axis relative to printed circuit board. Projection of one of the lugs comes into gear with cut in printed circuit board and is displaced aside between snapping brackets in such a way that snapping brackets are not able to come into gear with locks for snapping, if lug projection does not come into gear with cut. Monitor version includes monitor, used in zones with magnetic and HF fields and connecting electronic circuits for processing of ECG signals. In method of subject control in magnetic field magnetic resonance system is used, with control of subject's physiological being carried out by means of electrodes; vertical displacement, rocking and transverse rotation of connector are prevented, and information from electrodes to monitor is transmitted via leads.

EFFECT: more reliable and stable connection of leads of electrodes with printed circuit board and prevention of incorrect connection of connector with printed circuit board are ensured.

14 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: quick recording and remote transmission of the physiological parameters of human and animal cardiovascular and respiratory systems experimentally is enabled by using a receiver comprising three recording units of signal picking-up and transmission from three patients or animals simultaneously. Each of them comprises three piezoelectric detectors for ECG recording and one strain gauge for respiration depth and rate recording - a respiratory potential. The receiver is provided with a bioelectrical amplifier, an analogue-to-digital converter, RS485 interface with a board providing digital signal coding, conversion and transmission in the form of a radio signal. The latter is trapped by means of Bluetooth adapter with using a radio signal receiving and ECG and respiratory potential transmission unit. Each unit channel is checked up to receive signals from its recorder and to transmit to an ECG and respiration processing and storage unit arranged at a distance up to 30 m from the recorder. It comprises a laptop with a screen displaying one channel of cardio signal and respiratory potential channels independently from each patient or animal. Each patient or animal's data can be saved as a separate file on the signal processing and storage unit.

EFFECT: method provides fast, qualitative real-time recording of the physiological parameters with creating the conditions of a distant control of the patients both in hospitals and polyclinics, and in remote locations, in emergency and other abnormal situations.

7 dwg

Up!